Trial Profile
A Phase I, Randomized, Subject And Investigator Blind, Sponsor Open, Multiple Escalating Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Healthy Adult Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Nov 2019
Price :
$35
*
At a glance
- Drugs Pesampator (Primary)
- Indications Cognition disorders
- Focus Pharmacokinetics
- Sponsors Pfizer
- 25 Jan 2012 New trial record